-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...

-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for affordable Medicines in the country will actually be one only when there is a pro-patient slant to the...

-The Times of India MUMBAI: You could be popping certain pills and combinations that are illegally approved, harmful, cleared without proper clinical trials or even banned in the US and other countries. Delivering a severe rap on the government's knuckles, a parliamentary standing committee on health has charged it with "dilly-dallying and procrastination'' over serious irregularities in approval of life-saving Medicines, not following the global ban on harmful drugs, and failing...

-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...

-The Times of India As many as 2,644 people, called subjects, died during the clinical trials of 475 new drugs on human beings in last seven years and only 17 of the Medicines were approved for marketing in India, the Centre has informed the Supreme Court. Responding to allegations by NGO, Swasthya Adhikar Manch, in its PIL that Indians were used as guinea pigs by foreign pharmaceutical majors for human trial of...